Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia

Advances in Therapy

Volumn 28, Issue SUPPL. 3, 2011, Pages 1-9

  Font, Patricia ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Acute myeloid leukemia; Azacitidine; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTIEMETIC AGENT; AZACITIDINE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; RETINOIC ACID; THALIDOMIDE; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COMPARATIVE EFFECTIVENESS; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; INFECTION; INJECTION SITE REACTION; KARYOTYPE; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENOMICS; PRACTICE GUIDELINE; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; SEPSIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BONE MARROW; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79959805760     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0002-8     Document Type: Review

References (33)

1. Silverman LR. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS) Oncologist. 2001;6(suppl. 5):8-14.
2. Leone G, Teofili L, Voso MT, Lübbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87:1324-1341. (Pubitemid 36005306)
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088. (Pubitemid 27132124)
4. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
5. Vidaza® EPAR-Product Information. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000978/ WC500050239.pdf). Accessed February 1, 2011.
6. Fenaux P, Mufti G, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223-232.
7. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. V.2.2011. Available at: http://www.nccn.org/professionals/physician-gls. Accessed January 30, 2011.
8. Appelbaum F, Gundacker H, Head D, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-3485.
9. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-1098.
10. Deschler B, de Witte T, Mertelsmann R, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006;91:1513-1522. (Pubitemid 44736118)
11. Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109:5129-5135. (Pubitemid 46900774)
12. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440. (Pubitemid 34525728)
13. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7:21-29. (Pubitemid 23184796)
14. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199. (Pubitemid 12073508)
15. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903. (Pubitemid 46630737)
16. Kornblith AB, Herndon JE 2nd, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441-2452. (Pubitemid 34525729)
17. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in older adult patients with low bone marrow blast count (20-30%) acute myeloid leukemia. J Clin Oncol. 2009;28:562-569.
18. Rowe JM, Neuberg D, Friedenberg W, et al; Eastern Cooperative Oncology. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479-485.
19. Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85:130-138.
20. Fenaux P, Bowen D, Gattermann N, et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res. 2010;34:1410-1416.
21. Thépot S, Itzykson R, Seegers V, et al. Azacytidine (AZA) as first line therapy in AML: results of the French ATU program. Blood (ASH Annual Meeting Abstracts). 2009;114:843.
22. Itzykson R, Thépot S, Recher C, et al. Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU program. Blood (ASH Annual Meeting Abstracts). 2009;114:1054.
23. Itzykson R, Thépot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117:403-411.
24. Grövdal M, Karimi M, Khan R, et al. Maintenance treatment with azacytidine for patients with highrisk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010;150:293-302.
25. Gardin C, Prébet T, Bouabdallah K, et al. A phase II study of post-remission therapy with azacitidine (AZA) in patients with AML post-MDS and highrisk MDS: a GFM group study. Blood (ASH Annual Meeting Abstracts). 2009;114:844.
26. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302-2308. (Pubitemid 47523148)
27. Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma. 2008;49:2141-2147.
28. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113:1596-1604.
29. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium. J Clin Oncol. 2008;26(suppl.). Abstract 7000.
30. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009;115:1899-1905.
31. Vigil C, Cortes J, Kantarjian H, Garcia-Manero G, Lancet E, List A. Hypomethylating therapy for the treatment of acute erythroleukemia patients. Blood (ASH Annual Meeting Abstracts). 2009;114:2069.
32. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-1803.
33. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. V.2.2010. Available at: http://www.nccn.org/professionals/physician-gls. Accessed January 30, 2011.